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last accessed). This isolate (submitted in 2010) originated from
Poland and is described as methicillin susceptible. Multilocus
sequence typing showed that the isolate belonged to the novel
sequence type ST2497, a single-locus variant of ST1943 with
one nucleotide difference in the glpF gene.
The isolate described in this study represents the first detec-
tion of an mecC-containing MRSA from an animal host in
Norway. The mecC gene has been detected recently in a total
of eight MRSA isolates from humans in Norway7 (and
K. W. Larssen, unpublished data). All eight mecC MRSAs, isolated
during 2006–12, belonged to CC130. The genotype of the feline
isolate represents a new mecC-positive genotype identified in our
country; however, isolates within this clonal lineage with mecC
have been described from other countries.1,4
The detection of mecC in an MRSA from a clinical sample from a
cat submitted to our diagnostic bacteriological service unit demon-
strates the importance of taking mecC into consideration in diag-
nostic units that examine samples from companion animals. Our
finding extends our knowledge of MRSA carrying mecC from
animals and demonstrates that detection of mecC is not only a
rare event when screening historical isolate collections.
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Sir,
The prevalence of natural polymorphisms and mutations asso-
ciated with integrase (IN) inhibitor (INI) resistance in the HIV-1
IN has already been analysed.1 – 5 The aim of the study was to
characterize the HIV-1 IN variability in antiretroviral (ARV)-naive
and -experienced patients, never treated with INIs, in a panel
of different HIV-1 subtypes, and the relationship with drug resist-
ance. This multicentre study included 590 HIV-1-infected indivi-
duals never treated with INIs (308 drug-naive and 282
ARV-experienced patients) who were enrolled in seven clinical
centres in France and one centre in Switzerland. Nucleotide
and amino acid sequences were compared with the HxB2
HIV-1 clade B consensus sequence (GenBank accession
number K03455.1) using the Bioedit software program. The
sequences of the samples have been submitted to GenBank
and assigned accession numbers JX425421 to JX425885 and
JX451875 to JX451963. Thirty-seven of the 590 sequences are
not available in the NCBI database because we have only the
description of the polymorphism for these sequences and not
the nucleotide sequence. The median CD4+ T cell count at the
time the samples were drawn was 280 CD4+ T cells/mm3
(range 2–1692) and the median log10 viral load was 4.43 log10
copies/mL (1.92–6.94). Drug-treated patients were exposed to
an average of 1.96+2.65 nucleotide reverse transcriptase inhibi-
tors (n¼526), 0.18+0.41 non-nucleoside reverse transcriptase
inhibitors (n¼473) and 0.86+1.59 protease inhibitors
(n¼481). The entire IN protein sequences (288 amino acids)
derived from 308 drug-naive and 282 experienced patients
infected with HIV-1 B or non-B subtype, all INI-naive, were
analysed (Figure 1). All important residues involved in catalytic
activity or in binding to the human cellular cofactor LEDGF/p75
were conserved in both drug-naive and ARV-treated patients
(variability ,0.5%). The presence of polymorphic substitutions
at codon 124 was significantly associated with previous ARV
exposure (P¼0.03). Limited data are available on the preva-
lence of specific polymorphisms in the IN gene of HIV-1
non-B subtypes. We investigated the diversity of the IN
region of different HIV-1 subtypes in INI-naive patients.
Among the 590 samples, 252 corresponded to non-B sub-
types. No difference in reverse transcriptase and IN sequences
was observed between subtypes. Twenty-six changes were
found with significantly different prevalence between B iso-
lates and at least one non-B group (prevalence of polymorph-
ism .50%; P,0.05). Polymorphisms at codons D10, K14, S17,
A21, S24, D25, V31, V32, S39, V72, L101, T112, T125, G134,
I135, K136, D167, V201, T206, I208, K215, T218, L234,
D256, D278 and S283 could be related to specific non-B sub-
types. Among the 26 analysed codons, we analysed the
T125A mutations. T125A (specific GCA codon) was significantly
more prevalent in non-B samples (P,0.0001). A similar result
was found in a recent study on the analysis of polymorphisms
in the IN gene of ART-naive patients infected with HIV-1 non-B
subtypes.6
Twenty-two out of 36 HIV-1 IN resistance mutations (H51Y,
L68I/V, V72I, L74M, Q95K, T97A, S119G/R, A128T, T125K,
V151I, M154I, K156N, E157Q, K160N, G163K/R, V165I, V201I,
I203M, T206S, S230N, D232N and V249I) already associated
with INI resistance were detected. Polymorphic changes
included some known residues associated with INI resistance,
such as V72I, L74M, T97A, V151I, E157Q and I203M, but were
not statistically different between ARV-naive and -experienced
patients not including INIs. In contrast, the frequency of L101I
and T124A mutations, but not the M154I mutation, selected in
vitro by dolutegravir was higher in naive patients. Regarding
viral subtypes, mutations L101I and T124A, either alone or in
combination, were significantly more prevalent in non-B than B
subtypes in ARV-naive patients (65.5% versus 34.6% for L101I,
74.4% versus 25.6% for T124A and 85.7% versus 14.3% for
L101I+T124A; P,0.0001 in all cases), as recently described by
Garrido et al.7 Except at position 157 (E157Q), none of the
primary mutations detected in patients failing on raltegravir-
containing regimens (Y143R/C, Q148H/K/R and N155H) or on
elvitegravir-containing regimens (T66I, E92Q, E138K, S147G,
Q148H/K/R and N155H) was detected. The E157Q mutation
was observed among 2.9% (n¼17) of patient samples, including
four of subtype B, one of subtype H, seven of subtype CRF02_AG,
one of subtype A, two of subtype D, one of subtype CRF11_cpx
and one of subtype G, without a significant difference in poly-
morphism between ARV-naive and -experienced patients. The
primary mutations detected in patients failing on dolutegravir-
containing regimens (V151L, S153Y, T66K/L74M, E92Q/N155H,
E138A/K+Q148H/K/R, G140C/S+Q148H/K/R and Q148R/N155H)
were completely absent.
In our study, dolutegravir resistance-associated mutations, in
particular R263K, were not found to be polymorphic. Only the
mutations L101I and T124A, which were previously shown to
be selected in vitro in the presence of dolutegravir8,9 either
alone or in combination, were common in both naive and experi-
enced patients. However, these mutations have shown little
impact on virological response to dolutegravir. Recently, the
HIV-1 CRF01_AE IN coding region of the pol gene was evaluated
for the presence of natural polymorphisms in 87 ARV-naive indi-
viduals from Cambodia, Thailand and Vietnam.10 Amino acid
substitutions occurred in 60% of the subjects and none of
these substitutions have been reported to be associated with re-
sistance to INIs. Many polymorphisms in non-B viruses are con-
sidered to be secondary resistance mutations since they emerge
in B subtype viruses after drug exposure.11 Nevertheless, the se-
lection of resistance mutations could be influenced by the natur-
ally occurring variations between the different non-B subtypes.
In conclusion, all patients in our study lacked previously
described major resistance mutations to raltegravir, elvitegravir
and dolutegravir. However, we found evidence of important var-
iations regarding the IN polymorphisms according to the differ-
ent HIV-1 subtypes. Further studies of INI-treated patients will
be needed to fully elucidate the role of polymorphic IN muta-
tions in the context of HIV-1 variability.
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Figure 1. Distribution of variants among group M HIV-1 IN sequences. Amino acid polymorphism in HIV-1 IN from 308 plasma samples from
drug-naive patients and 282 samples from experienced patients are reported. The consensus subtype B sequence is shown in bold at the top of
each 30 amino acid section. Numbers given as superscripts below each position are the numbers of isolates with that specific polymorphism. Grey
boxes signify positions associated with in vivo resistance defined according to the algorithms from the ANRS (update October 2012, v.22, http://
www.hivfrenchresistance.org/2012/Algo-sep-2012.pdf). Highly conserved motifs, the HHCC motif (coordinates zinc binding), the DDE motif,
catalytic core domains I–VI and the Q sequence, are indicated by boxes.
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Sir,
Limited data are available regarding interactions between tacro-
limus and commonly used highly active antiretroviral therapies,
such as first-line nucleoside reverse transcriptase inhibitors, non-
nucleoside reverse transcriptase inhibitors (NNRTIs) and some
protease inhibitors (PIs). When first-line combinations are con-
traindicated and newer antiretroviral agents are required, there
are even less data on the interactions between newer agents
such as maraviroc (a CCR5 inhibitor) with immunosuppressants
such as tacrolimus (a calcineurin inhibitor). There are some
animal model data of the beneficial effects on cardiac allograft
survival when using maraviroc alongside immunosuppressants,
with the potential that CCR5 inhibition could improve long-term
outcomes after transplantation.1,2 In our patient undergoing
hepatic transplant, with limited antiretroviral therapy options
and the necessity to be started on a newer agent, we set out
to observe concentrations of the immunosuppressant tacrolimus
before and after administration of maraviroc to ensure that
effective and non-toxic concentrations of both drugs were
achieved.
We describe a 49-year-old man from Sierra Leone, recently
diagnosed with fully sensitive HIV clade C and chronic hepatitis
B virus (HBV). After routine blood tests revealed abnormal liver
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